GlucoLight advances trials with extra series C funding:
This article was originally published in Clinica
Bethlehem, Pennsylvania-based start-up GlucoLight is pushing forward clinical trials of its Sentris-100 noninvasive, continuous blood glucose monitoring technology, after raising additional funds from the third tranche of its series C financing round. The amount of investment raised was not disclosed. The new financing, provided by Life Sciences Greenhouse, Robin Hood Ventures and private investors, will also be used to initiate development of a miniaturised, commercial version of GlucoLight's technology.